AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04716335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Harmine)
Description: Placebo for Harmine
Study NCT02991001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT02991001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT02991001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study NCT03685604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHX disinfection
Description: CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Study NCT04716335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (DMT)
Description: Placebo for DMT
Study NCT04716335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (DMT)
Description: Placebo for DMT
Study NCT03041974 — intervention group
Intervention type: PROCEDURE
Intervention: Red Blood Cell transfusion
Study NCT03041974 — intervention group
Intervention type: PROCEDURE
Intervention: Microparticles quantification
Description: Flow cytometric quantification of microparticles in transfused blood
Study NCT02703064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Furocyst
Description: Furocyst caps BD
Study NCT00677599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid enrichment (cocoa / soy compounds)
Description: Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
Study NCT00677599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavonoid enrichment (cocoa / soy compounds)
Description: 27g placebo chocolate bar to be consumed for 365 days.
Study NCT03693859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement program
Description: The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
Study NCT03693859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss + Health Segments
Description: Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
Study NCT01637948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine mouthrinse
Description: For six months
Study NCT01637948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine mouthrinse
Description: six months
Study NCT02955147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
Study NCT02955147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is an anti-inflammatory medication
Study NCT03573076 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy with Methyl Aminolevulinate creme and red light.
Study NCT03573076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ablative Thulium laser (NAFL)
Description: Non-ablative Thulium laser (NAFL).
Study NCT03685604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI Disinfection
Description: PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
Study NCT03573076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative Thulium laser (NAFL)
Description: Non-ablative Thulium laser (NAFL).
Study NCT03573076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency microneedles (RF-MN)
Description: Radio-frequency microneedles (RF-MN).
Study NCT03573076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency microneedles (RF-MN)
Description: Radio-frequency microneedles (RF-MN).
Study NCT03888157 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Study NCT03993600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)
Description: three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects
Study NCT03993600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)
Description: three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects
Study NCT04411160 — intervention group
Intervention type: DRUG
Intervention: Vitamin C
Description: 4 gram of vitamin c slowly intravenous once daily for 4 days duration.
Study NCT04411160 — intervention group
Intervention type: DRUG
Intervention: Nitric Oxide
Description: nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
Study NCT04411160 — intervention group
Intervention type: DEVICE
Intervention: ventilators
Description: All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
Study NCT02757690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-dimensional distal pancreatectomy
Description: 3D laparoscopy
Study NCT02757690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-dimensional distal pancreatectomy
Description: 2D laparoscopy
Study NCT04097353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harvesting Hope for Kids (HH4K)
Description: Weekly meetings at university-based farm
Study NCT04097353 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Surviving Strong for Kids (SS4K)
Description: Enhanced usual care
Study NCT02675205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel: efficacy and safety in cerebral aneurysm stenting
Study NCT04179942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fractional exhaled nitric oxide and CRP levels
Description: measurement of FeNO and Hs-CRP after 3months of CPAP
Study NCT04179942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Fractional exhaled nitric oxide and CRP levels
Description: measurement of FeNO and Hs-CRP after 3months of CPAP
Study NCT03003455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation over a bougie
Description: Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
Study NCT03003455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nasotracheal Intubation
Description: Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
Study NCT01044017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study NCT01044017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: single oral doses
Study NCT00673400 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stapled transanal rectum resection
Description: Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
Study NCT02311231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
Study NCT02311231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
Study NCT02615002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piromelatine
Study NCT02615002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03262142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Intravenous Piperacillin/tazobactam four times daily
Study NCT03262142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Oral Ciprofloxacin twice daily
Study NCT02675205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: ticagrelor:efficacy and safety in cerebral aneurysm stenting
Study NCT02675205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Study NCT02675205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Study NCT03818360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an evidence-based smoking cessation intervention comprising brief advice plus active referrals
Description: The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
Study NCT01877239 — intervention group
Intervention type: OTHER
Intervention: non-intervention
Description: observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
Study NCT03097081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No orthosis
Description: The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
Study NCT03097081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthosis
Description: Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
Study NCT02237729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06410293
Description: PF-06410293 will be administered as a single 40 mg, subcutaneous dose
Study NCT02237729 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-US
Description: Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
Study NCT02237729 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-EU
Description: Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
Study NCT03947307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lymphtaping using Easytape®
Description: lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
Study NCT03947307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compression treatment
Description: manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
Study NCT03947307 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taping
Description: sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
Study NCT02982824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Oral magnesium
Study NCT02982824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Placebo will be given
Study NCT02408601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helioseal - F
Description: Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepeted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion
Study NCT02408601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART sealant
Description: Fuji IX extra strength~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes.
Study NCT02527642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
Study NCT02527642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embryo culture in buffered media
Description: compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
Study NCT00817700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Sleep restriction.
Study NCT03764527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Two doses a day for 3 days, under supervision
Study NCT03764527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coadministered Artesunate plus Amodiaquine
Description: One dose a day for 3 days, under supervision
Study NCT01109927 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Insulin
Description: Insulin treatment in accordance to glucose values
Study NCT01109927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin treatment in accordance to glucose values
Study NCT04189952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.
Study NCT04189952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.
Study NCT00535613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: IV, single bolus at completion of anesthetic, 0.1 ml/kg
Study NCT00535613 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: IV, single bolus at completion of anesthetic, 0.1 ml/kg
Study NCT03404245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, Fitbit/self-management app, physiotherapist counselling.
Description: Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
Study NCT03404245 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 6 month delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
Study NCT03311555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240mg tablet daily for 36 weeks
Study NCT03311555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
Study NCT03311555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy
Description: On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
Study NCT03311555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
Study NCT02461212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
Study NCT04189952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.
Study NCT04189952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.
Study NCT04371016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verticalization (bed)
Description: The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes.~At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method
Study NCT00315341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.